Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Stat of the Week: Hospital M&A up 40% in Q4:17
Hospital M&A activity accelerated in the fourth quarter of 2017. The number of hospital acquisitions rose to 21 in the fourth quarter, up 40% from the 15 publicly announced acquisitions in the third quarter of 2017. Compared with the same quarter in 2016, which posted 23 transactions, activity was down 9%. None of the transactions disclosed a purchase price in the third quarter of 2017. Four of the deals disclosed prices, for a combined total of $2.82 billion. None of the transactions in the third quarter disclosed a price, although the fourth quarter of 2016 posted a total of $2.31 billion. The largest deal in the quarter was UnitedHealth Group’s (NYSE: UNH) $2.8 billion acquisition... Read More »
New MainStream Adds On to Platform Companies
The recent crop of healthcare services platforms owned by New MainStream Capital is moving to the add-on stage. Last week brought two acquisition announcements from Omni Eye Services and CORDENTAL Group. Both companies were acquired in 2017. New MainStream committed $25 million in equity capital to buy CORDENTAL in March 2017. The Cincinnati-based company is a dental support organization that provides business support services to affiliated dental practices in the Mid-Atlanta, Midwestern and Southeastern regions. Omni Eye Services, based in Iselin, New Jersey, is an optometric referral practice providing a full range of specialty services for the advanced treatment of eye diseases. No... Read More »
Allscripts Adds Practice Fusion
Allscripts Healthcare Solutions (NASDAQ: MDRX) is back in buying mode. The healthcare technology company announced two deals back in August 2017, picking off McKesson’s (NYSE: MCK) hospital and health IT portfolio for $185 million, and then NantHealth’s (NASDAQ: NH) electronic health record (EHR) assets for an undisclosed price. This time, the target is Practice Fusion, a Silicon Valley startup focused on creating affordable certified cloud-based EHR systems for small, independent physician practices. As small as that market may seem, the company now supports 30,000 ambulatory practices and 5 million patient visits per month. The deal is a strategic one for Allscripts,... Read More »
The Physician Medical Group Market Ramps Up
The Physician Medical Group (PMG) space is consolidating at a torrid pace, and the pace won’t slacken in 2018. Last year, deals for physician practices hit a record in the 21st century with 166 transactions, up 27% over the previous year’s 131 transactions. The momentum is indeed continuing into 2018, with eight more acquisitions announced in the first two weeks. The real record was set in 1998, at 264 deals, but that was a very different time and market. Then, publicly traded management companies were building nationwide platforms of physicians. The market collapsed in 1999, and most of those transactions were unwound and the deal makers vowed, “Never again.” Welcome to 2018.... Read More »
Stat of the Week: PE Firms Accounted for 10% of 2017 Deals
2017 was a busy year for healthcare mergers and acquisitions, with 1,566 transactions announced. At this early date, that total is 2% below the previous year’s total of 1,593 (a record year, by the way). Private equity firms contributed to that total, announcing 158 transactions, or 10% of the annual total, according to data obtained from our DealSearchOnline.com database. That total is equal to the previous year’s 156 announced transactions. Private equity firms typically don’t disclose financial terms when they announce transactions (if they announce them at all), so it’s interesting to see these firms did disclose some $22.0 billion on healthcare transactions in... Read More »Health Care M&A Weekly Deals, The Week Ending January 12, 2018
We hope you are enjoying your membership to HealthCareMandA.com. This Health Care M&A Weekly chart below is a selection of transactions announced during the prior week(s). The deals presented here are further elaborated in the monthly newsletter, Health Care M&A News, and in the quarterly report. This information also appears in our online database, Deal Search Online. Visit www.dealsearchonline.com to open a guest account and begin your search. Behavioral Health Care Acquirer Target Price Five Arrows Capital Partners The Stepping Stones Group N/A Biotechnology Acquirer Target Price Zymergen Inc. Radiant Genomics N/A Agilent Technologies Inc. Luxcel Biosciences N/A Celgene... Read More »
Deal of the Week: Celgene/Impact
Biotechnology deals are off to a strong start in 2018, thanks to the Biotech Showcase 2018 held every year alongside the J.P. Morgan Healthcare Conference. In the first two weeks, 16 transactions were made public. This year, the Showcase registration desk was just getting into full swing on Sunday, January 7, when Celgene Corp. (NASDAQ: CELG) announced its $1.1 billion acquisition of Impact Biomedicines, a privately held biotech based in San Diego. The draw is Impact’s lead product candidate, fedratinib, a highly selective JAK2 kinase inhibitor that is being evaluated for myelofibrosis and polycythemia vera. Fedratinib was evaluated in 877 patients across 18 clinical trials. In a... Read More »Health Care M&A Weekly Deals, The Week Ending January 5, 2018
We hope you are enjoying your membership to HealthCareMandA.com. This Health Care M&A Weekly chart below is a selection of transactions announced during the prior week(s). The deals presented here are further elaborated in the monthly newsletter, Health Care M&A News, and in the quarterly report. This information also appears in our online database, Deal Search Online. Visit www.dealsearchonline.com to open a guest account and begin your search. Biotechnology Acquirer Target Price Pfizer Inc. Collaboration on PROTACs N/A Roche Research collaboration on novel bispecific molecule $10 million Biocrates Life Sciences AG Metanomics Health GmbH N/A Reckitt... Read More »
Deal of the Week: Takeda/TiGenix
Japanese pharmaceutical giant Takeda Pharmaceutical Company Limited (TSE: 4502) declared its intention to acquire 100% of the voting rights it doesn’t already own in the Dutch biotechnology company TiGenix NV (NASDAQ: TIG). Takeda is offering $627 million in cash, representing an 82% premium over TiGenix’s closing price prior to the date when the news of the deal broke. On January 5, 2018, the day the news broke, TIG stock shot up nearly 71%, to $40.75. TiGenix is an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells. Upon the acquisition, TiGenix will become a subsidiary of Takeda. The... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
